Literature DB >> 10585479

Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.

V E Anderson1, R P Zaniewski, F S Kaczmarek, T D Gootz, N Osheroff.   

Abstract

Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA cleavage mediated by prokaryotic type II topoisomerases. Although topoisomerase IV appears to be the primary cytotoxic target for most quinolones in Gram-positive bacteria, interactions between the enzyme and these drugs are poorly understood. Therefore, the effects of ciprofloxacin on the DNA cleavage and religation reactions of Staphylococcus aureus topoisomerase IV were characterized. Ciprofloxacin doubled DNA scission at 150 nM drug and increased cleavage approximately 9-fold at 5 microM. Furthermore, it dramatically inhibited rates of DNA religation mediated by S. aureus topoisomerase IV. This inhibition of religation is in marked contrast to the effects of antineoplastic quinolones on eukaryotic topoisomerase II, and suggests that the mechanistic basis for quinolone action against type II topoisomerases has not been maintained across evolutionary boundaries. The apparent change in quinolone mechanism was not caused by an overt difference in the drug interaction domain on topoisomerase IV. Therefore, we propose that the mechanistic basis for quinolone action is regulated by subtle changes in drug orientation within the enzyme.drug.DNA ternary complex rather than gross differences in the site of drug binding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585479     DOI: 10.1074/jbc.274.50.35927

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

2.  Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Authors:  Sonia K Morgan-Linnell; Hiroshi Hiasa; Lynn Zechiedrich; John L Nitiss
Journal:  Curr Protoc Pharmacol       Date:  2007-12

Review 3.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

4.  Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Benjamin H Williamson; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2015-01-23       Impact factor: 3.162

5.  Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1.

Authors:  R Kirk; A Ratcliffe; G Noonan; M Uosis-Martin; D Lyth; O Bardell-Cox; J Massam; P Schofield; S Hindley; D R Jones; J Maclean; A Smith; V Savage; S Mohmed; C Charrier; A-M Salisbury; E Moyo; R Metzger; N Chalam-Judge; J Cheung; N R Stokes; S Best; M Craighead; R Armer; A Huxley
Journal:  RSC Med Chem       Date:  2020-09-18

6.  Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

Authors:  Gunther Kern; Tiffany Palmer; David E Ehmann; Adam B Shapiro; Beth Andrews; Gregory S Basarab; Peter Doig; Jun Fan; Ning Gao; Scott D Mills; John Mueller; Shubha Sriram; Jason Thresher; Grant K Walkup
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

7.  Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Authors:  S Roychoudhury; C E Catrenich; E J McIntosh; H D McKeever; K M Makin; P M Koenigs; B Ledoussal
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  Bioflavonoids as poisons of human topoisomerase II alpha and II beta.

Authors:  Omari J Bandele; Neil Osheroff
Journal:  Biochemistry       Date:  2007-04-26       Impact factor: 3.162

9.  Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV.

Authors:  Steven L Pitts; Grace F Liou; Lesley A Mitchenall; Alex B Burgin; Anthony Maxwell; Keir C Neuman; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2011-02-07       Impact factor: 16.971

10.  Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2013-03-04       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.